Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a systematic review of the literature
Surgery is the mainstay therapy for pancreatic neuroendocrine tumors (P-NETs) but it is associated with significant adverse events. EUS-RFA has been described as a safe and effective treatment for treating P-nets. It may be reasonable to consider EUS -RFA for small P-NETS, irrespective of the functional status, we say.
Endoscopic Ultrasound-Guided Gallbladder Drainage Versus Percutaneous Transhepatic Gallbladder Drainage for Acute Cholecystitis with High Surgical Risk: An Up-to-Date Meta-Analysis and Systematic Review
Study compared EUSGBD with percutaneous transhepatic gallbladder drainage (PTGBD) for acute cholecystitis with high surgical risk. EUS GBD was associated with less reintervention and readmission. With lumen-apposing metal stents (LAMS), E USGBD was linked to fewer adverse events. Technical success with PTGBD, however, was higher than that with EusGBD.
Diagnostic yield of endoscopic ultrasound-guided tissue acquisition in autoimmune pancreatitis: a systematic review and meta-analysis
There is limited evidence on the diagnostic performance of endoscopic ultrasound (EUS)-guided tissue acquisition in autoimmune pancreatitis (AIP) 15 studies with 631 patients were included, of which four were prospective series and one randomized trial. Overall diagnostic accuracy of EUS tissue acquisition was 54.7% (95% confidence interval, 40.9%-68.4%) with a clear superiority of FNB over FNA. FNB provided level 1 of histological diagnosis in 44.2% of cases (30.8%-57.5%) as compared to 21.9% w
Comparison of Three Methods of Gallbladder Drainage for Patients with Acute Cholecystitis Who Are at High Surgical Risk: A Network Meta-Analysis and Systematic Review
Percutaneous gallbladder drainage is used for the treatment of patients with acute cholecystitis who are at high surgical risk. It is unclear which procedure is associated with the best outcomes. EUSGBD appears to be preferable with respect to both safety and efficacy, say authors. The study looked at 13 studies that compared at least two of the drainage procedures.
Combined chemotherapy and EUS-guided intra-tumoral 32-P implantation for locally advanced pancreatic ductal adenocarcinoma: a pilot study
This study evaluated clinical outcomes of combined chemotherapy and Endoscopic Ultrasound (EUS) guided intra-tumoral radioactive phosphorus-32 (32P OncoSil) implantation in locally advanced pancreatic adenocarcinoma (LAPC). Technical success was 100% and no procedural complications were reported.EUS guided 32P OncoSil implantation is feasible and well tolerated and was associated with a 42% rate of surgical resection in our cohort.
Endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) technique and analgesic efficacy in patients with pancreatic cancer: A systematic review and meta-analysis
Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) can be used to treat abdominal pain in pancreatic cancer. It can be administered in three different ways, depending on the site of needle insertion: central injection, bilateral injection and celiac ganglia neurolysis. There was no evidence of a difference in response rates between the three techniques. Serious complications have been reported for BI and CGN but not for CI.
EUS-guided pelvic drainage: A systematic review and meta-analysis
EUS-guided pelvic abscess drainage is a procedure that uses an echoendoscope to visualize an area of interest for needle insertion and placement of a stent, catheter, or both for drainage of the target abscess. Eight studies with a total of 135 patients combined were included in our analysis. The rate of technical success was 100% and the pooled rate of clinical success was 92% (95% confidence interval [CI]: 87%, 98%; P = 0.31; I2 = 15%) The calculated pooled rates of adverse events was 9.4% wit
Favorable effect of endoscopic reassessment of clinically staged T2 esophageal adenocarcinoma: a multicenter, prospective cohort study
Clinical tumor stage of esophageal adenocarcinoma is determined by endoscopic ultrasound and/or CT-scan. accuracy of these tools is low for stages T1 and T2, which may result in overtreatment. We aimed to assess the proportion of cT2 EAC downstaged to cT1 after endoscopic reassessment.ERA downstages about half of the cT2 tumors to cT1 suitable for ER. ERA has a substantial clinical impact on therapeutic management preventing overtreatment in 40% of patients.